JANX
Janux Therapeutics, Inc.$14.24+0.10 (+0.67%)Prev Close$14.15·MCap$826.9M·P/E—·Vol431.8K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
11
$1.06M
◆
Net Activity
Net Seller
$1.06M
●
Active Insiders
7
last 12 mo
Over the past 12 months, insider activity at Janux Therapeutics, Inc. (JANX) has been exclusively selling, with 0 insider purchases totaling $0.00 and 11 insider sales totaling $1.06M. The most recent insider transaction was by Doyle Janeen Noel (officer: Chief Corp. & Bus. Dev. Ofcr), who sold $56.9K worth of shares on Jun 4, 2026. Janux Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $826.9M.
JANX Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | Doyle Janeen Noel | officer: Chief Corp. & Bus. Dev. Ofcr | Sell | 4,059 | $14.03 | $56.9K | 75,941 |
| May 13, 2026 | Dobek Maria | officer: Vice President, Accounting | Sell | 2,038 | $14.17 | $28.9K | 32,270 |
| Jan 2, 2026 | Campbell David Alan | President and CEO | Sell | 8,072 | $13.73 | $110.8K | 0 |
| Jan 2, 2026 | DiRaimondo Thomas | Chief Scientific Officer | Sell | 2,505 | $13.73 | $34.4K | 0 |
| Jan 2, 2026 | Dobek Maria | Vice President, Accounting | Sell | 1,462 | $13.73 | $20.1K | 0 |
| Jan 2, 2026 | McIver Zachariah | Chief Medical Officer | Sell | 2,714 | $13.73 | $37.3K | 0 |
| Jan 2, 2026 | Meyer Andrew Hollman | Chief Business Officer | Sell | 1,879 | $13.73 | $25.8K | 0 |
| Jan 2, 2026 | Winter Charles M. | Chief Technical Officer | Sell | 2,401 | $13.73 | $33.0K | 0 |
| Dec 1, 2025 | Meyer Andrew Hollman | Chief Business Officer | Sell | 3,333 | $32.98 | $109.9K | 0 |
| Nov 14, 2025 | Meyer Andrew Hollman | Chief Business Officer | Sell | 3,333 | $30.00 | $100.0K | 0 |
| Oct 28, 2025 | Meyer Andrew Hollman | Chief Business Officer | Sell | 16,665 | $30.06 | $501.0K | 0 |
| May 1, 2025 | Meyer Andrew Hollman | Chief Business Officer | Sell | 3,333 | $32.03 | $106.7K | 0 |
| Apr 21, 2025 | Meyer Andrew Hollman | Chief Business Officer | Sell | 3,334 | $30.00 | $100.0K | 0 |
| Mar 3, 2025 | Meyer Andrew Hollman | Chief Business Officer | Sell | 3,334 | $32.15 | $107.2K | 0 |
| Feb 5, 2025 | Meyer Andrew Hollman | Chief Business Officer | Sell | 3,334 | $42.29 | $141.0K | 83,055 |
| Jan 8, 2025 | Campbell David Alan | President and CEO | Sell | 5,000 | $60.00 | $300.0K | 293,054 |
| Jan 3, 2025 | Meyer Andrew Hollman | Chief Business Officer | Sell | 13,334 | $54.88 | $731.8K | 92,551 |
| Dec 27, 2024 | Campbell David Alan | President and CEO | Sell | 25,000 | $56.19 | $1.40M | 217,054 |
| Dec 3, 2024 | Campbell David Alan | President and CEO | Sell | 15,000 | $67.00 | $1.00M | 242,054 |
| Nov 27, 2024 | Campbell David Alan | President and CEO | Sell | 25,000 | $51.60 | $1.29M | 263,773 |
| Oct 30, 2024 | Campbell David Alan | President and CEO | Sell | 25,000 | $53.54 | $1.34M | 293,157 |
| Oct 24, 2024 | Lichter Jay | Sell | 3,815 | $46.68 | $178.1K | 7,000-35% | |
| Oct 22, 2024 | RA CAPITAL MANAGEMENT, L.P. | Buy | 1,200,000 | $44.75 | $53.70M2.0% OS | 9,317,246 | |
| Oct 18, 2024 | Avalon Ventures XI, L.P. | Sell | 1,673,128 | $46.30 | $77.47M2.8% OS | 2,819,366-37% | |
| Sep 30, 2024 | Avalon Ventures XI, L.P. | Sell | 307,779 | $46.96 | $14.45M0.5% OS | 2,970,875 | |
| Sep 27, 2024 | Campbell David Alan | President and CEO | Sell | 25,000 | $46.31 | $1.16M | 313,097 |
| Sep 27, 2024 | DiRaimondo Thomas | Chief Scientific Officer | Sell | 5,000 | $46.34 | $231.7K | 98,613 |
| Sep 27, 2024 | Meyer Andrew Hollman | Chief Business Officer | Sell | 50,000 | $45.96 | $2.30M | 67,592-43% |
| Sep 12, 2024 | Avalon Ventures XI, L.P. | Sell | 451,091 | $46.89 | $21.15M0.7% OS | 3,217,817 | |
| Sep 10, 2024 | Avalon Ventures XI, L.P. | Sell | 242,182 | $42.00 | $10.17M | 3,229,374 | |
| Jun 5, 2024 | Lichter Jay | Sell | 1,500,000 | $54.75 | $82.13M2.5% OS | 3,340,018-31% | |
| Nov 15, 2023 | Reardon Tighe | Acting Chief Financial Officer | Buy | 849,854 | $5.87 | $4.99M1.4% OS | 849,854 |
| Jul 21, 2023 | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | 495,008 | $12.46 | $6.17M0.8% OS | 8,117,246 |
| Dec 30, 2021 | ORBIMED ADVISORS LLC | Director | Sell | 40,400 | $20.30 | $820.1K | 2,258,566 |
| Dec 23, 2021 | ORBIMED ADVISORS LLC | Director | Sell | 119,400 | $19.00 | $2.27M | 2,295,266 |
| Dec 17, 2021 | Thompson Peter A. | Director | Sell | 393,300 | $19.07 | $7.50M0.6% OS | 2,403,566 |
| Jun 16, 2021 | Bregua Corp | 10% Owner | Buy | 58,823 | $17.00 | $1000.0K | 3,749,250 |
| Jun 16, 2021 | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | 2,941,176 | $17.00 | $50.00M4.8% OS | 7,622,238+63% |
| Jun 16, 2021 | Reardon Tighe | Acting Chief Financial Officer | Buy | 629,411 | $17.00 | $10.70M1.0% OS | 4,479,492 |
| Jun 16, 2021 | Thompson Peter A. | Director | Buy | 705,853 | $17.00 | $12.00M1.2% OS | 2,760,366+34% |
JANX Insider Buying Activity
The following table shows recent insider purchases of Janux Therapeutics, Inc. (JANX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Oct 22, 2024 | RA CAPITAL MANAGEMENT, L.P. | Buy | 1,200,000 | $44.75 | $53.70M2.0% OS | 9,317,246 | |
| Nov 15, 2023 | Reardon Tighe | Acting Chief Financial Officer | Buy | 849,854 | $5.87 | $4.99M1.4% OS | 849,854 |
| Jul 21, 2023 | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | 495,008 | $12.46 | $6.17M0.8% OS | 8,117,246 |
| Jun 16, 2021 | Bregua Corp | 10% Owner | Buy | 58,823 | $17.00 | $1000.0K | 3,749,250 |
| Jun 16, 2021 | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | 2,941,176 | $17.00 | $50.00M4.8% OS | 7,622,238+63% |
| Jun 16, 2021 | Reardon Tighe | Acting Chief Financial Officer | Buy | 629,411 | $17.00 | $10.70M1.0% OS | 4,479,492 |
| Jun 16, 2021 | Thompson Peter A. | Director | Buy | 705,853 | $17.00 | $12.00M1.2% OS | 2,760,366+34% |
JANX Insider Selling Activity
The following table shows recent insider sales of Janux Therapeutics, Inc. (JANX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | Doyle Janeen Noel | officer: Chief Corp. & Bus. Dev. Ofcr | Sell | 4,059 | $14.03 | $56.9K | 75,941 |
| May 13, 2026 | Dobek Maria | officer: Vice President, Accounting | Sell | 2,038 | $14.17 | $28.9K | 32,270 |
| Jan 2, 2026 | Campbell David Alan | President and CEO | Sell | 8,072 | $13.73 | $110.8K | 0 |
| Jan 2, 2026 | DiRaimondo Thomas | Chief Scientific Officer | Sell | 2,505 | $13.73 | $34.4K | 0 |
| Jan 2, 2026 | Dobek Maria | Vice President, Accounting | Sell | 1,462 | $13.73 | $20.1K | 0 |
| Jan 2, 2026 | McIver Zachariah | Chief Medical Officer | Sell | 2,714 | $13.73 | $37.3K | 0 |
| Jan 2, 2026 | Meyer Andrew Hollman | Chief Business Officer | Sell | 1,879 | $13.73 | $25.8K | 0 |
| Jan 2, 2026 | Winter Charles M. | Chief Technical Officer | Sell | 2,401 | $13.73 | $33.0K | 0 |
| Dec 1, 2025 | Meyer Andrew Hollman | Chief Business Officer | Sell | 3,333 | $32.98 | $109.9K | 0 |
| Nov 14, 2025 | Meyer Andrew Hollman | Chief Business Officer | Sell | 3,333 | $30.00 | $100.0K | 0 |
| Oct 28, 2025 | Meyer Andrew Hollman | Chief Business Officer | Sell | 16,665 | $30.06 | $501.0K | 0 |
| May 1, 2025 | Meyer Andrew Hollman | Chief Business Officer | Sell | 3,333 | $32.03 | $106.7K | 0 |
| Apr 21, 2025 | Meyer Andrew Hollman | Chief Business Officer | Sell | 3,334 | $30.00 | $100.0K | 0 |
| Mar 3, 2025 | Meyer Andrew Hollman | Chief Business Officer | Sell | 3,334 | $32.15 | $107.2K | 0 |
| Feb 5, 2025 | Meyer Andrew Hollman | Chief Business Officer | Sell | 3,334 | $42.29 | $141.0K | 83,055 |
| Jan 8, 2025 | Campbell David Alan | President and CEO | Sell | 5,000 | $60.00 | $300.0K | 293,054 |
| Jan 3, 2025 | Meyer Andrew Hollman | Chief Business Officer | Sell | 13,334 | $54.88 | $731.8K | 92,551 |
| Dec 27, 2024 | Campbell David Alan | President and CEO | Sell | 25,000 | $56.19 | $1.40M | 217,054 |
| Dec 3, 2024 | Campbell David Alan | President and CEO | Sell | 15,000 | $67.00 | $1.00M | 242,054 |
| Nov 27, 2024 | Campbell David Alan | President and CEO | Sell | 25,000 | $51.60 | $1.29M | 263,773 |
| Oct 30, 2024 | Campbell David Alan | President and CEO | Sell | 25,000 | $53.54 | $1.34M | 293,157 |
| Oct 24, 2024 | Lichter Jay | Sell | 3,815 | $46.68 | $178.1K | 7,000-35% | |
| Oct 18, 2024 | Avalon Ventures XI, L.P. | Sell | 1,673,128 | $46.30 | $77.47M2.8% OS | 2,819,366-37% | |
| Sep 30, 2024 | Avalon Ventures XI, L.P. | Sell | 307,779 | $46.96 | $14.45M0.5% OS | 2,970,875 | |
| Sep 27, 2024 | Campbell David Alan | President and CEO | Sell | 25,000 | $46.31 | $1.16M | 313,097 |
| Sep 27, 2024 | DiRaimondo Thomas | Chief Scientific Officer | Sell | 5,000 | $46.34 | $231.7K | 98,613 |
| Sep 27, 2024 | Meyer Andrew Hollman | Chief Business Officer | Sell | 50,000 | $45.96 | $2.30M | 67,592-43% |
| Sep 12, 2024 | Avalon Ventures XI, L.P. | Sell | 451,091 | $46.89 | $21.15M0.7% OS | 3,217,817 | |
| Sep 10, 2024 | Avalon Ventures XI, L.P. | Sell | 242,182 | $42.00 | $10.17M | 3,229,374 | |
| Jun 5, 2024 | Lichter Jay | Sell | 1,500,000 | $54.75 | $82.13M2.5% OS | 3,340,018-31% | |
| Dec 30, 2021 | ORBIMED ADVISORS LLC | Director | Sell | 40,400 | $20.30 | $820.1K | 2,258,566 |
| Dec 23, 2021 | ORBIMED ADVISORS LLC | Director | Sell | 119,400 | $19.00 | $2.27M | 2,295,266 |
| Dec 17, 2021 | Thompson Peter A. | Director | Sell | 393,300 | $19.07 | $7.50M0.6% OS | 2,403,566 |
JANX Insiders
Similar Stocks to JANX
VRTX
Vertex Pharmaceuticals Incorporated
$452.32-1.39%
$112.92B
REGN
Regeneron Pharmaceuticals, Inc.
$603.05-0.74%
$63.06B
ALNY
Alnylam Pharmaceuticals, Inc.
$277.24-1.96%
$37.76B
RVMD
Revolution Medicines, Inc.
$161.40+2.30%
$34.03B
UTHR
United Therapeutics Corporation
$540.50-2.02%
$23.27B
MRNA
Moderna, Inc.
$63.56+2.49%
$21.98B
INSM
Insmed Incorporated
$95.08-3.47%
$20.70B
INCY
Incyte Corporation
$97.84-1.18%
$19.93B